 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...4950515253545556575859...208209» |
- ||||| GSK5784283 / GSK
New P2 trial: A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma (clinicaltrials.gov) - Dec 26, 2024
P2, N=300, Not yet recruiting, Sponsor: GlaxoSmithKline
- | AiTan (rivoceranib) / HLB Bio Group, Keytruda (pembrolizumab) / Merck (MSD), Kaitanni (cadonilimab) / Akesobio
Journal: Successful conversion surgery after comprehensive therapy in a patient with MSI-H but pMMR metastatic gastric mixed adenoneuroendocrine carcinoma: a case report and literature review. (Pubmed Central) - Dec 26, 2024
A 68-year-old male with metastatic gastric MANEC was treated with targeted therapy, immunotherapy, and chemotherapy, including S-1, apatinib, cadonilimab, and paclitaxel...The patient was subsequently treated with a maintenance regimen of S-1 and pembrolizumab...While conversion surgery can be effective in certain contexts, the high likelihood of postoperative recurrence and metastasis, particularly in neuroendocrine components, necessitates cautious consideration. Further research is needed to evaluate the long-term benefits of conversion surgery in metastatic gastric MANEC and to develop tailored therapeutic strategies.
- || AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment closed: SHR-1316-202: A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer (clinicaltrials.gov) - Dec 26, 2024
P2, N=56, Active, not recruiting, Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
Further research is needed to evaluate the long-term benefits of conversion surgery in metastatic gastric MANEC and to develop tailored therapeutic strategies. Recruiting --> Active, not recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma. (Pubmed Central) - Dec 25, 2024
The combined group contained 33 patients (56.9%) who experienced temporary post-embolization symptoms. For BCLC-C HCC patients, TACE may significantly increase the therapeutic effectiveness of camrelizumab-rivoceranib without increasing the risk of camrelizumab-rivoceranib-related complications.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
P2 data, Journal, Tumor mutational burden, Metastases: Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial. (Pubmed Central) - Dec 23, 2024
P2
Importantly, no grade 4 or higher treatment-related adverse events or deaths were reported, indicating a favorable safety profile. In conclusion, the combination of pyrotinib and fulvestrant demonstrated promising antitumor activity and acceptable safety in HR-positive/HER2-positive metastatic breast cancer patients.
- || Keytruda (pembrolizumab) / Merck (MSD), AiRuiKa (camrelizumab) / HLB Bio Group
Clinical, Retrospective data, Review, Journal, Metastases: Comparison of the efficacy and safety of perioperative immunochemotherapeutic strategies for locally advanced esophageal cancer: a systematic review and network meta-analysis. (Pubmed Central) - Dec 23, 2024
Our study suggests that evaluating the efficacy and safety of different ICIs may be helpful in clinical decision-making. https://www.crd.york.ac.uk/prospero/, identifier CRD42024583548.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China. (Pubmed Central) - Dec 23, 2024
Sensitivity analysis further verified that these findings were robust across various assumptions. The combination of camrelizumab and rivoceranib as a treatment strategy not only improves health outcomes but also represents a cost-effective option across different developmental regions in China.
- || Review, Journal: Antibodies to watch in 2025. (Pubmed Central) - Dec 23, 2024
The combination of camrelizumab and rivoceranib as a treatment strategy not only improves health outcomes but also represents a cost-effective option across different developmental regions in China. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA
- ||| vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Clinical, P3 data, Journal: Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial. (Pubmed Central) - Dec 21, 2024
P3
In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA Vunakizumab demonstrated robust clinical response at week 12 and through week 52, with good tolerability in moderate-to-severe plaque psoriasis.
- | AiTan (rivoceranib) / HLB Bio Group, Epidaza (chidamide) / Chipscreen, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer (clinicaltrials.gov) - Dec 20, 2024
P2, N=63, Not yet recruiting, Sponsor: Peking University
- ||| AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: SHR-1316-SCLC-LN-001: Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Dec 20, 2024
P=N/A, N=38, Recruiting, Sponsor: Yunpeng Liu
Vunakizumab demonstrated robust clinical response at week 12 and through week 52, with good tolerability in moderate-to-severe plaque psoriasis. Not yet recruiting --> Recruiting
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Enrollment closed, Trial completion date, Real-world evidence: Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 20, 2024
P=N/A, N=200, Active, not recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Feb 2025
- | tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Trial initiation date: Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Dec 20, 2024
P2, N=32, Not yet recruiting, Sponsor: Fudan University
Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Feb 2025 Initiation date: Jul 2024 --> Dec 2024
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P2 trial: Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer (clinicaltrials.gov) - Dec 20, 2024
P2, N=30, Not yet recruiting, Sponsor: Peking University Cancer Hospital & Institute
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: The efficacy of plasma exosomal miRNAs as predictive biomarkers for PD-1 blockade plus chemotherapy in gastric cancer. (Pubmed Central) - Dec 19, 2024
The response of gastric cancer (GC) patients to first-line programmed cell death 1 (PD-1) blockade and S-1 plus oxaliplatin (SOX) chemotherapy varies considerably, and the underlying mechanisms driving this variability remain elusive...Serum exosomes were extracted from 11 GC patients (five in the primary cohort and six in the validation cohort) treated with SOX and camrelizumab (a PD-1 inhibitor)...This study identified specific plasma exosomal miRNAs in GC patients that differ between responders and non-responders to PD-1 monoclonal antibody therapy combined with chemotherapy. These miRNAs could serve as predictive biomarkers, paving the way for precision medicine and personalized therapy in the treatment of GC.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal, Real-world evidence, Real-world, Metastases: Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28). (Pubmed Central) - Dec 19, 2024
P
Palbociclib, abemaciclib, and dalpiciclib demonstrated comparable efficacy in Chinese patients with advanced HR+/HER2- MBC. ClinicalTrials.gov identifier: NCT06344780.
- | Enrollment change: Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov) - Dec 19, 2024
P2, N=10, Recruiting, Sponsor: Peking Union Medical College
ClinicalTrials.gov identifier: NCT06344780. N=30 --> 10
- MODULE 4: Promising Investigational Front-Line Strategies for Advanced HCC (San Francisco Marriott Marquis, Golden Gate Ballroom ) - Dec 19, 2024 - Abstract #ASCOGI2025ASCO_GI_993;
N=30 --> 10 This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Eisai Inc.
- || HRS2398 / Jiangsu Hengrui Pharma
Trial completion, Enrollment change, Trial primary completion date, First-in-human: A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - Dec 18, 2024
P1, N=28, Completed, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Eisai Inc. Recruiting --> Completed | N=122 --> 28 | Trial primary completion date: May 2023 --> Feb 2024
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC (clinicaltrials.gov) - Dec 18, 2024
P2, N=120, Recruiting, Sponsor: Guangzhou Institute of Respiratory Disease
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 18, 2024
P=N/A, N=32, Recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2/3 trial: MA-HCC-II/III-030: SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. (clinicaltrials.gov) - Dec 18, 2024
P2/3, N=398, Not yet recruiting, Sponsor: Sun Yat-sen University
- |||||||||| SHR-A2102 / Jiangsu Hengrui Pharma
New P3 trial: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Dec 18, 2024
P3, N=402, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1/2 trial: HAICI: Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=10, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital
- ||| Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma
Clinical, P3 data, Journal, Combination therapy, Patient reported outcomes, Metastases: Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study. (Pubmed Central) - Dec 18, 2024
P3
Additionally, the REZ-ADT group demonstrated a prolonged delay in the deterioration of the total score on the FACT-P questionnaire (25th percentile, 12.8 [95% CI 7.4-20.3] vs. 6.0 months [95% CI 4.6-9.2]; HR 0.66 [95% CI 0.50-0.86]; p?=?0.002), as well as most of the FACT-P subscale scores, in comparison to the BIC-ADT group. In conclusion, REZ-ADT is superior to BIC-ADT regarding the pain alleviation and enhancement of functional scales for high-volume mHSPC.
- || Review, Journal: Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy. (Pubmed Central) - Dec 18, 2024
Moreover, the primary focus will be on the underlying mechanism of action as well as the clinical efficacy of bioactive molecules. Current challenges along with the scope of future research directions targeting PD-1/PD-L1 interactions through natural substances are also discussed.
- | Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: HAIBrave-001: HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 18, 2024
P2, N=78, Recruiting, Sponsor: Sun Yat-sen University
- ||| NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo (clinicaltrials.gov) - Dec 18, 2024
P4, N=216, Active, not recruiting, Sponsor: Bausch & Lomb Incorporated
Current challenges along with the scope of future research directions targeting PD-1/PD-L1 interactions through natural substances are also discussed. Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Nov 2025 | Trial primary completion date: Feb 2026 --> Nov 2025
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial completion date, Trial termination: Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Dec 17, 2024
P1/2, N=46, Terminated, Sponsor: Henan Cancer Hospital
Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Nov 2025 | Trial primary completion date: Feb 2026 --> Nov 2025 Trial completion date: Jan 2026 --> Jul 2024 | Active, not recruiting --> Terminated; Investigators' decision
- Fruzaqla (fruquintinib) / Takeda, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study (UNION TNT). (Level 1, West Hall; Poster Bd #: H4) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_872;
P2
This treatment strategy might be a potential option as neoadjuvant therapy for high-risk LARC pts. Updated data will be presented in the future.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Clinical outcomes of camrelizumab + rivoceranib vs sorafenib (CARES-310) as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC) of non-viral and viral etiology. (Level 1, West Hall; Poster Bd #: C4) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_536;
P3
HCC, hepatocellular carcinoma; mOS, median overall survival; mPFS, median progression-free survival; mo, months; HR, hazard ratio; HCV, hepatitis C virus; HBV, hepatitis B virus, NR, not reached. Results used Cox proportional hazard model.
- AiRuiKa (camrelizumab) / HLB Bio Group
Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial). (Level 1, West Hall; Poster Bd #: B22) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_512;
P2
From March 2020 to June 2022, a total of 93 ECC/GBC patients after curative resection were randomized 1:1 into chemoradiation-anti-PD-1 group (n=46, Camrelizumab + concurrent Capecitabine and radiotherapy) and observation group (n=47). Chemoradiation combined with immunotherapy as an adjuvant therapy demonstrated superior survival outcomes over observation in resectable ECC/GBC patients with a well-tolerable safety profile, supporting the potential of this combination treatment as effective adjuvant therapy for these high-risk patients.
- sonesitatug vedotin (AZD0901) / AstraZeneca
CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC). (Level 1, West Hall; Poster Bd #: K11) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_386;
P3
Previously presented at European Society for Medical Oncology - Gastrointestinal Cancers Congress 2024, Final Publication Number: 495TiP, Kohei Shitara et al. Reused with permission.
- AiRuiKa (camrelizumab) / HLB Bio Group
Use of immune repertoire sequencing analysis to detect differences in treatment responses for advanced esophageal squamous cell carcinoma treated with camrelizumab and platinum-based chemotherapy. (Level 1, West Hall; Poster Bd #: H3) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_371;
P4
IR sequencing may provide insights into the underlying mechanisms influencing treatment response. Objective response and disease response.*p<0.05, a statistically difference.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Neoadjuvant adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: A phase 2 trial. (Level 1, West Hall; Poster Bd #: F8) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_329;
P2
Neoadjuvant adebrelimab plus chemotherapy shows promising pathological response and favorable safety profile in patients with resectable locally advanced ESCC. Survival follow-up is ongoing.
- Aqupla (nedaplatin) / Simcere, Fruzaqla (fruquintinib) / Takeda, AiRuiKa (camrelizumab) / HLB Bio Group
Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial. (Level 1, West Hall; Poster Bd #: F10) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_308;
P1/2
Survival follow-up is ongoing. The combination of fruquintinib, camrelizumab, paclitaxel liposome, and nedaplatin demonstrated significant efficacy and manageable toxicity profiles as a first-line treatment for advanced ESCC, suggesting a potential new treatment strategy.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study. (Level 1, West Hall; Poster Bd #: E11) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_285;
P2
Neoadjuvant adebrelimab combined with chemotherapy and adjuvant adebrelimab demonstrated encouraging clinical efficacy and manageable safety in pts with LA-ESCC. Further study is warranted.
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Bifunctional anti-PD-L1/TGF-?RII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Survival results of a phase II trial. (Level 1, West Hall; Poster Bd #: D26) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_277;
P=N/A
Eligible pts received SHR-1701 (30mg/kg, iv, d1, q3w) in combination with up to six cycles of albumin-bound paclitaxel (125mg/m2, iv, d1, d8, q3w) and cisplatin (75mg/m2, iv, d1, q3w). The results highlighted that SHR-1701 plus chemotherapy as first-line therapy maintained long-term, durable survival benefit in pts with advanced ESCC.
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-?RII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial. (Level 1, West Hall; Poster Bd #: D24) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_276;
P=N/A
Preoperative therapy included SHR-1701 (30 mg/kg every 3 weeks for 2 cycles), albumin paclitaxel (50 mg/m2, once a week for 5 weeks), carboplatin (AUC=2, once a week for 5 weeks) and radiotherapy (41.4Gy in 23 fractions). The addition of SHR-1701 to neoadjuvant chemoradiotherapy in ESCC demonstrated promising efficacy with acceptable toxicity, and might be a promising approach for neoadjuvant treatment.
- Efficacy of PD-1 inhibitor plus chemotherapy versus chemotherapy in advanced esophageal carcinoma: A meta-analysis of phase III clinical trials. (Level 1, West Hall; Poster Bd #: D11) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_263;
PD-1 inhibitors against EC included nivolumab, pembrolizumab, camrelizumab, sintilimab, toripalimab, and serplulimab. PD-1 inhibitor plus chemotherapy as a first-line therapy in advanced EC, mainly in patients with CPS ?10, showed improved antitumor efficacy in terms of superior ORR, OS, and PFS, with a manageable toxicity profile providing a benchmark for future studies.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, open-label, randomized, phase 2 study (CAP-ACE). (Level 2, Ballroom) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_163;
P=N/A
PD-1 inhibitor plus chemotherapy as a first-line therapy in advanced EC, mainly in patients with CPS ?10, showed improved antitumor efficacy in terms of superior ORR, OS, and PFS, with a manageable toxicity profile providing a benchmark for future studies. The addition of camrelizumab and apatinib to TACE can significantly prolong progression-free survival in patients with unresectable HCC eligible for embolization, with a manageable safety profile.
- AiRuiKa (camrelizumab) / HLB Bio Group
Conversion effects of PD-1 inhibitor camrelizumab (Cam) combined with Nab-POF regimen in patients (pts) with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma: FDZL-001 trial. (Level 2, Ballroom) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_152;
P2
The PD-1 inhibitor Cam combined with the Nab-POF regimen safely induced a high conversion rate with very high R0 resection and high 3-year PFS and OS rates, preliminarily demonstrating promising effects, providing a new conversion drug treatment option for pts with initially unresectable locally advanced or limited metastatic advanced GC. These findings warrant further prospective, randomized controlled investigations.
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Effect of SHR-1701 on chemotherapy (chemo)-induced myelosuppression: Data from a phase 3 study in HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA). (Level 2, Ballroom) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_151;
P3
SHR-1701 showed the capacity to suppress chemo-associated myelosuppression. Safety.
- || Review, Journal: Current Treatment Methods in Hepatocellular Carcinoma. (Pubmed Central) - Dec 17, 2024
Moreover, to maximize outcomes for patients with HCC, the combination of immune checkpoint inhibitors (ICIs) along with targeted therapies or local ablative therapy is being investigated. This review elaborates on the current status of HCC treatment, outlining the most recent clinical study results and novel approaches.
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. (Pubmed Central) - Dec 16, 2024
P2/3
Elevated baseline lactate dehydrogenase was linked to shorter PFS. SHR-1701 combined with XELOX and bevacizumab demonstrated a manageable safety profile and potent antitumor activity in unresectable mCRC.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: P2RX1-blocked neutrophils induce CD8+ T cell dysfunction and affect the immune escape of gastric cancer cells. (Pubmed Central) - Dec 16, 2024
SHR-1701 combined with XELOX and bevacizumab demonstrated a manageable safety profile and potent antitumor activity in unresectable mCRC. This project validated that the loss of P2RX1 in neutrophils induces CD8+ T cell dysfunction and affects the GC development, indicating that P2RX1 may be an accurate biomarker for predicting ICI response, thus providing a theoretical basis for the clinical application of ICI.
- || AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1 trial: MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 16, 2024
P1, N=40, Not yet recruiting, Sponsor: Guangdong Provincial People's Hospital
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open, Trial completion date, Trial primary completion date: Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC (clinicaltrials.gov) - Dec 16, 2024
P2, N=35, Recruiting, Sponsor: Beijing Chest Hospital, Capital Medical University
This project validated that the loss of P2RX1 in neutrophils induces CD8+ T cell dysfunction and affects the GC development, indicating that P2RX1 may be an accurate biomarker for predicting ICI response, thus providing a theoretical basis for the clinical application of ICI. Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Aug 2026
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion, Trial completion date, IO biomarker: Neoadjuvant Immunotherapy for Resectable Gastric Cancer (clinicaltrials.gov) - Dec 16, 2024
P2, N=25, Completed, Sponsor: Qilu Hospital of Shandong University
Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Aug 2026 Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024
- | Avastin (bevacizumab) / Roche, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P2 trial, Combination therapy, Monotherapy, Metastases: Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer (clinicaltrials.gov) - Dec 15, 2024
P2, N=105, Recruiting, Sponsor: Qilu Hospital of Shandong University